Gilead, looking for cancer sales, swipes Roche pharma chief Daniel O'Day for CEO post
With Gilead's CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that in the ranks of the world's biggest cancer drug maker.
The Big Biotech has poached longtime Roche exec Daniel O'Day, who'll take the helm at Gilead on March 1. O'Day heads up pharma operations for the Swiss drugmaker, which has long led the industry in the oncology sales department.
RELATED: Gilead's top executives Milligan and Martin steppi...